CN100526332C - 内皮抑制素用于生产治疗视网膜疾病药物的用途 - Google Patents

内皮抑制素用于生产治疗视网膜疾病药物的用途 Download PDF

Info

Publication number
CN100526332C
CN100526332C CNB038231344A CN03823134A CN100526332C CN 100526332 C CN100526332 C CN 100526332C CN B038231344 A CNB038231344 A CN B038231344A CN 03823134 A CN03823134 A CN 03823134A CN 100526332 C CN100526332 C CN 100526332C
Authority
CN
China
Prior art keywords
endostatin
purposes
individuality
significant quantity
micro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038231344A
Other languages
English (en)
Chinese (zh)
Other versions
CN1708513A (zh
Inventor
P·A·坎普契亚罗
M·卡莱克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100526332(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1708513A publication Critical patent/CN1708513A/zh
Application granted granted Critical
Publication of CN100526332C publication Critical patent/CN100526332C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
CNB038231344A 2002-08-28 2003-08-27 内皮抑制素用于生产治疗视网膜疾病药物的用途 Expired - Fee Related CN100526332C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40647002P 2002-08-28 2002-08-28
US60/406,470 2002-08-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910150526A Division CN101637611A (zh) 2002-08-28 2003-08-27 眼的基因治疗

Publications (2)

Publication Number Publication Date
CN1708513A CN1708513A (zh) 2005-12-14
CN100526332C true CN100526332C (zh) 2009-08-12

Family

ID=31978303

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB038231344A Expired - Fee Related CN100526332C (zh) 2002-08-28 2003-08-27 内皮抑制素用于生产治疗视网膜疾病药物的用途
CN200910150526A Pending CN101637611A (zh) 2002-08-28 2003-08-27 眼的基因治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200910150526A Pending CN101637611A (zh) 2002-08-28 2003-08-27 眼的基因治疗

Country Status (11)

Country Link
US (1) US20070104684A1 (enExample)
EP (1) EP1534751B1 (enExample)
JP (1) JP4612417B2 (enExample)
CN (2) CN100526332C (enExample)
AT (1) ATE464321T1 (enExample)
AU (1) AU2003258675B2 (enExample)
CA (1) CA2496820A1 (enExample)
DE (1) DE60332122D1 (enExample)
IL (1) IL166950A (enExample)
NZ (1) NZ538958A (enExample)
WO (1) WO2004020469A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
WO2001093897A2 (en) * 2000-06-02 2001-12-13 Entremed, Inc. Angiostatin and endostatin binding proteins and methods of use
WO2002030982A2 (en) * 2000-10-13 2002-04-18 Entremed, Inc. Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174861B1 (en) 1996-10-22 2001-01-16 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein
DE69830663T2 (de) * 1997-09-24 2006-05-11 The Regents Of The University Of California, Oakland Nicht-Primaten-Lentivirus-Vektoren und Verpackungssysteme
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
US6670321B1 (en) * 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
AU2001295193A1 (en) * 2000-05-01 2001-11-12 Novartis Ag Vectors for ocular transduction and use thereof for genetic therapy
EP1401480B1 (en) * 2001-02-22 2012-11-28 Novartis AG Viral vectors encoding endostatin in the treatment of ocular neovascularization
WO2003066810A2 (en) * 2002-02-04 2003-08-14 Novartis Ag Recombinant bovine immunodeficiency virus based gene transfer system
AU2003226349B2 (en) * 2002-04-11 2008-01-31 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
WO2004028635A1 (en) * 2002-09-27 2004-04-08 Novartis Ag Ocular gene therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
WO2001093897A2 (en) * 2000-06-02 2001-12-13 Entremed, Inc. Angiostatin and endostatin binding proteins and methods of use
WO2002030982A2 (en) * 2000-10-13 2002-04-18 Entremed, Inc. Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
blokade of vascular endothelial cell growth factor receptor signaling is sufficient to completely preventretinal neovascularization. Hiroaki Qzaki等.American journal of patboloy,Vol.156 No.2. 2000
blokade of vascular endothelial cell growth factor receptor signaling is sufficient to completely preventretinal neovascularization. Hiroaki Qzaki等.American journal of patboloy,Vol.156 No.2. 2000 *
inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment. Kyoko Ohno-Matsui等.American journal of patbology,Vol.1620 No.2. 2000
inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Keisuke Mori 等.American journal of patbology,Vol.159 No.1. 2001

Also Published As

Publication number Publication date
EP1534751B1 (en) 2010-04-14
IL166950A (en) 2011-04-28
JP4612417B2 (ja) 2011-01-12
CN101637611A (zh) 2010-02-03
AU2003258675A1 (en) 2004-03-19
DE60332122D1 (de) 2010-05-27
CA2496820A1 (en) 2004-03-11
ATE464321T1 (de) 2010-04-15
CN1708513A (zh) 2005-12-14
EP1534751A2 (en) 2005-06-01
HK1077306A1 (en) 2006-02-10
NZ538958A (en) 2006-09-29
WO2004020469A3 (en) 2004-04-29
WO2004020469A2 (en) 2004-03-11
JP2006516112A (ja) 2006-06-22
AU2003258675B2 (en) 2009-03-26
US20070104684A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
US8338384B2 (en) Method for treating ocular neovascularization
Lai et al. Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model
US7989426B2 (en) Selective induction of apoptosis to treat ocular disease by expression of PEDF
WO2002026827A1 (en) Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
US20060251621A1 (en) Ocular gene therapy
Prea et al. Gene therapy with endogenous inhibitors of angiogenesis for neovascular age‐related macular degeneration: beyond anti‐VEGF therapy
Kreppel et al. Long-term transgene expression in the RPE after gene transfer with a high-capacity adenoviral vector
AU780634C (en) Gene Therapy for treating ocular-related disorders
KR19990066967A (ko) 비정상적인 망막 혈관형성을 치료하기 위한 유전자 치료법과vegf 안티센스용 dna 운반체로써 사용되는 히알루론산
JP2006518741A (ja) ａｔｏｎａｌ関連因子をコードするベクターを投与することによる耳疾患を治療するための遺伝子治療法
CN100526332C (zh) 内皮抑制素用于生产治疗视网膜疾病药物的用途
US20230135501A1 (en) Gene therapy
HK1077306B (en) Ocular gene therapy
RU2846105C1 (ru) Аденоассоциированный вирус для доставки kh902 (конберцепта) и его применения
WO2025103416A1 (zh) 用于老年相关性黄斑变性的治疗的基因治疗药物
JP2022119955A (ja) 血管新生阻害剤としてのｃ型レクチンであるレベセチン
Stephens Development of gene therapy for the treatment of inherited retinal degeneration
Tombran-Tink New Experimental Therapeutic Approaches for Degenerative Diseases of the Retina
COTLIER et al. Gene Therapy for Genetic and Acquired Retinal Diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090812

CF01 Termination of patent right due to non-payment of annual fee